Results 181 to 190 of about 3,258,233 (341)
Deinococcus radiodurans‐derived extracellular vesicles (R1‐EVs) provide radioprotection against total‐body irradiation‐induced acute radiation syndrome in mice. R1‐EVs mitigate oxidative damage by scavenging free radicals, promoting intestinal repair, enhancing hematopoietic function, and modulating immune responses. This study highlights the potential
Jeong Moo Han+7 more
wiley +1 more source
A Machine Learning Algorithm to Predict Medical Device Recall by the Food and Drug Administration. [PDF]
Barbosa Slivinskis V+2 more
europepmc +1 more source
A summary of Food and Drug Administration‐reported adverse events and drug interactions occurring during therapy with omeprazole, lansoprazole and pantoprazole [PDF]
Joachim Labenz+3 more
openalex +1 more source
The top‐performing lipid nanoparticle, incorporating a novel ionizable lipid derived from vitamin B5, demonstrates high mRNA transfection efficiency, low toxicity, favorable stability, targeted delivery to lymphoid tissues, and high immunogenicity, showing promise as a carrier for mRNA vaccines for infectious diseases and cancer.
Soyeon Yoo+11 more
wiley +1 more source
Sam Greenhouse: his contributions as a consultant to the Food and Drug Administration [PDF]
Robert T. O’Neill
openalex +1 more source
Most in vitro cancer models lack cellular diversity, functional complexity, and clinical relevance. This work highlights the generation of an innovative dynamic tetraculture with autologous patient‐derived cells within a vascularized tumor‐on‐chip, as well as the recapitulation of endothelial anergy features induced by the tumor microenvironment ...
Christine Lansche+16 more
wiley +1 more source
Abemaciclib-associated kidney injuries: A retrospective analysis of the United States Food and Drug Administration adverse events reporting system. [PDF]
Xu X+7 more
europepmc +1 more source
Pediatric Drug Research: Food and Drug Administration Should More Efficiently Monitor Inclusion of Minority Children [PDF]
openalex +1 more source
Glepaglutide (GL), a GLP‐2 analog with an extended half‐life (50 h), is currently undergoing clinical trials for patients with short bowel syndrome. GL requires subcutaneous injection, which poses challenges for potential patient compliance. To address this challenge, we loaded GL into a rectal foam formulation using CO2 as a permeation enhancer to ...
Wunan Zhang+9 more
wiley +1 more source